https://scholars.lib.ntu.edu.tw/handle/123456789/551062
標題: | NIACE score refines the overall survival of hepatocellular carcinoma by Barcelona clinic liver cancer staging | 作者: | TUNG-HUNG SU SIH-HAN LIAO CHUN-MING HONG CHUN-JEN LIU TAI-CHUNG TSENG CHEN-HUA LIU HUNG-CHIH YANG PEI-JER CHEN DING-SHINN CHEN CHI-LING CHEN Adhoute X Bourlière M JIA-HORNG KAO |
公開日期: | 2019 | 出版社: | Blackwell Publishing | 卷: | 34 | 期: | 12 | 起(迄)頁: | 2179-2186 | 來源出版物: | Journal of Gastroenterology and Hepatology (Australia) | 摘要: | Background and Aim: The NIACE score provides prognostic values for hepatocellular carcinoma (HCC) in European studies. We aim to evaluate the prognostic value of the NIACE score in Asian patients. Methods: Patients with HCC were retrospectively enrolled from a tertiary medical center in Taiwan during 2009–2014, and their clinical information were collected. The NIACE score was calculated according to the Nodular numbers, tumor Infiltration, Alpha-fetoprotein level, Child–Pugh score, and Eastern Cooperative Oncology Group score. The prognostic values of NIACE score for overall survival according to individual treatment and the Barcelona clinic liver cancer (BCLC) staging were analyzed. Results: A total of 468 patients were included with a median follow-up of 30?months. A greater NIACE score correlated with lower median survival and higher BCLC staging. Regardless of treatment modalities, NIACE scores (0, 1–1.5, 2.5–3, and 4–7) significantly predicted survival between groups (log–rank P?0.001). Specifically, NIACE score (0, 1–1.5, 2.5–3, and 4–7) significantly predicted survival in patients receiving transarterial chemoembolization (log–rank P?0.001). NIACE score 1, 2.5, and 4 further distinguished overall survival in BCLC A, B, and C patients, respectively (all log–rank P?0.01). After adjustment of the confounders and the BCLC staging, NIACE score of 2.5–3 and 4–7 (vs 0) had a significantly increased risk of mortality with a hazard ratio of 4.04 (95% confidence interval: 2.14–7.64, P?0.001) and 7.45 (95% confidence interval: 3.22–17.23, P?0.001), respectively. Conclusions: The NIACE score helps refine differential prognosis among BCLC A, B, and C subgroups of Asian patients with HCC, especially in those receiving transarterial chemoembolization. ? 2019 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85068067305&doi=10.1111%2fjgh.14705&partnerID=40&md5=6ada783ad5c42d003fbdfbc2056a32f3 https://scholars.lib.ntu.edu.tw/handle/123456789/551062 |
ISSN: | 0815-9319 | DOI: | 10.1111/jgh.14705 | SDG/關鍵字: | alpha fetoprotein; sorafenib; adult; aged; alpha fetoprotein blood level; Article; Asian; cancer patient; cancer prognosis; cancer staging; cancer surgery; cancer survival; chemoembolization; Child Pugh score; female; follow up; human; liver cell carcinoma; major clinical study; male; multimodality cancer therapy; NIACE score; overall survival; priority journal; radiofrequency ablation; retrospective study; scoring system; survival prediction; systemic therapy; Taiwan; epidemiology; Kaplan Meier method; liver cell carcinoma; liver tumor; middle aged; mortality; pathology; predictive value; procedures; prognosis; severity of illness index; very elderly; young adult; Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Predictive Value of Tests; Prognosis; Retrospective Studies; Severity of Illness Index; Taiwan; Young Adult |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。